CA2717626A1 - Recombinant vaccinia virus having hepatitis c virus gene - Google Patents

Recombinant vaccinia virus having hepatitis c virus gene Download PDF

Info

Publication number
CA2717626A1
CA2717626A1 CA2717626A CA2717626A CA2717626A1 CA 2717626 A1 CA2717626 A1 CA 2717626A1 CA 2717626 A CA2717626 A CA 2717626A CA 2717626 A CA2717626 A CA 2717626A CA 2717626 A1 CA2717626 A1 CA 2717626A1
Authority
CA
Canada
Prior art keywords
virus
hepatitis
dna
nucleotide sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2717626A
Other languages
English (en)
French (fr)
Inventor
Michinori Kohara
Fukashi Murai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Metropolitan Institute of Medical Science
KM Biologics Co Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Tokyo Metropolitan Organization for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Tokyo Metropolitan Organization for Medical Research filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of CA2717626A1 publication Critical patent/CA2717626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2717626A 2008-03-07 2009-03-06 Recombinant vaccinia virus having hepatitis c virus gene Abandoned CA2717626A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-057515 2008-03-07
JP2008057515 2008-03-07
JP2008294361A JP5584407B2 (ja) 2008-03-07 2008-11-18 Ｃ型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス
JP2008-294361 2008-11-18
PCT/JP2009/054825 WO2009110644A1 (ja) 2008-03-07 2009-03-06 C型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス

Publications (1)

Publication Number Publication Date
CA2717626A1 true CA2717626A1 (en) 2009-09-11

Family

ID=41056188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717626A Abandoned CA2717626A1 (en) 2008-03-07 2009-03-06 Recombinant vaccinia virus having hepatitis c virus gene

Country Status (9)

Country Link
US (1) US9000136B2 (OSRAM)
EP (1) EP2267120B1 (OSRAM)
JP (1) JP5584407B2 (OSRAM)
KR (1) KR101607349B1 (OSRAM)
CN (1) CN101965396B (OSRAM)
AU (1) AU2009220401B2 (OSRAM)
CA (1) CA2717626A1 (OSRAM)
ES (1) ES2573704T3 (OSRAM)
WO (1) WO2009110644A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6013185B2 (ja) 2010-10-15 2016-10-25 公益財団法人東京都医学総合研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有する組換えワクシニアウイルス
EP2950817B1 (en) * 2013-01-31 2019-08-07 Portland State University Immunogenic compositions comprising silicified virus and methods of use
WO2014162031A1 (es) * 2013-04-02 2014-10-09 Consejo Superior De Investigaciones Científicas (Csic) Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapéuticas contra la hepatitis c
WO2016076441A1 (ja) * 2014-11-11 2016-05-19 公益財団法人東京都医学総合研究所 Ｃ型肝炎の治療及び／又は予防用医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06237773A (ja) 1992-12-22 1994-08-30 Tonen Corp ポックスウイルスのａ型封入体（ａｔｉ）プロモーター及び前期プロモーターを含んで成る外来遺伝子発現ベクター
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ
DE10143490C2 (de) 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
FR2855758B1 (fr) * 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
WO2005054451A1 (ja) * 2003-12-05 2005-06-16 Hokkaido Technology Licensing Office Co., Ltd. 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
CN102206663B (zh) * 2004-02-20 2014-02-05 公益财团法人东京都医学综合研究所 含人丙型肝炎病毒全长基因组的核酸构建物及其用途
WO2006013815A1 (ja) * 2004-08-02 2006-02-09 The Japan Health Sciences Foundation ＨＣＶウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
JP4665122B2 (ja) 2004-10-08 2011-04-06 財団法人 東京都医学研究機構 組み換えウイルスおよびその用途
JP2008057515A (ja) 2006-09-04 2008-03-13 Mitsubishi Heavy Ind Ltd ピックアップセンサの出力電圧判定方法および装置
JP5103058B2 (ja) 2007-05-28 2012-12-19 株式会社日立ハイテクノロジーズ 欠陥観察装置及び欠陥観察方法

Also Published As

Publication number Publication date
ES2573704T3 (es) 2016-06-09
AU2009220401B2 (en) 2015-07-30
EP2267120A1 (en) 2010-12-29
EP2267120A4 (en) 2012-06-27
AU2009220401A1 (en) 2009-09-11
US20110275139A1 (en) 2011-11-10
KR101607349B1 (ko) 2016-03-29
JP2009232836A (ja) 2009-10-15
CN101965396A (zh) 2011-02-02
EP2267120B1 (en) 2016-05-18
US9000136B2 (en) 2015-04-07
CN101965396B (zh) 2013-08-14
KR20100131480A (ko) 2010-12-15
WO2009110644A1 (ja) 2009-09-11
JP5584407B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
BR112020003470B1 (pt) Composições farmacêuticas compreendendo o vírus imunogênico de chikungunya chikv-delta5nsp3, processo e uso das mesmas
TW202203966A (zh) 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
KR20170068410A (ko) 엔테로바이러스 감염증에 대항하는 아데노바이러스 벡터-기반 백신
US20050053624A1 (en) West nile virus vaccine
AU2009220401B2 (en) Recombinant vaccinia virus having hepatitis C virus gene
JP6175167B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有する組換えワクシニアウイルス
US20090214587A1 (en) Recombinant virus and use thereof
EP3219323B1 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
JP5884100B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス
JPWO2006013815A1 (ja) ＨＣＶウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
JP5944210B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたｂ５ｒ遺伝子欠損組換えワクシニアウイルス
HK40085908A (en) Vaccines and uses thereof to induce an immune response to sars-cov2
Butler Structural and biological basis for the selection of cytotoxic lymphocyte escape variant viruses in mice infected with a coronavirus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140128

FZDE Discontinued

Effective date: 20220303